UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 77,775 Shares of Masimo Co. (NASDAQ:MASI)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 69.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 190,246 shares of the medical equipment provider's stock after acquiring an additional 77,775 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.36% of Masimo worth $31,448,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MASI. Jones Financial Companies Lllp bought a new position in shares of Masimo during the 4th quarter valued at $27,000. Blue Trust Inc. increased its holdings in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 71 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after buying an additional 64 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 60 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Masimo during the 4th quarter valued at about $46,000. 85.96% of the stock is currently owned by institutional investors.

Masimo Price Performance

Shares of MASI stock traded up $5.53 during trading hours on Friday, hitting $162.50. 1,073,631 shares of the company's stock were exchanged, compared to its average volume of 652,366. The stock's 50-day moving average is $157.30 and its 200-day moving average is $167.14. The stock has a market cap of $8.81 billion, a price-to-earnings ratio of 112.07 and a beta of 1.23. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, beating the consensus estimate of $1.24 by $0.12. The company had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business's revenue for the quarter was down 24.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 EPS. As a group, research analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Wells Fargo & Company cut their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Raymond James dropped their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating and issued a $200.00 price target (down previously from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. BTIG Research set a $193.00 price target on Masimo and gave the company a "buy" rating in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Thursday, April 10th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Masimo has a consensus rating of "Moderate Buy" and an average target price of $191.60.

Insiders Place Their Bets

In other news, COO Bilal Muhsin sold 30,000 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This represents a 55.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,053 shares of company stock valued at $6,998,565. 9.70% of the stock is currently owned by corporate insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.